Monoclonal antibody M195
Alternative Names: Aclizumab; Anti-CD33 monoclonal antibody M195; SMART M195; SMART M195 antibody; Zamyl™Latest Information Update: 17 Sep 2021
At a glance
- Originator Nonindustrial source
- Developer Nippon Organon; Nonindustrial source; PDL BioPharma
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Acute myeloid leukaemia; Acute promyelocytic leukaemia; Myeloid leukaemia; Preleukaemia
Most Recent Events
- 25 Aug 2002 Discontinued - Phase-I for Myeloid leukaemia in Japan (unspecified route)
- 25 Aug 2002 Discontinued - Phase-II for Acute promyelocytic leukaemia in USA (unspecified route)
- 25 Aug 2002 Discontinued - Phase-II for Preleukaemia (unspecified route)